PharmaTelevision - AusBiotech Evolves

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AusBiotech Evolves

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Despite the economic outlook in October 2008, Anna Lavelle describes the positive buzz that surrounded this year’s conference in Melbourne; the talk was not of negativity and gloom but of partnerships and collaborations. The biotech industry in Australia is used to challenges and has proved itself resilient, but as Dr Lavelle looks to the future she explains the importance of the role that Asia will play and why next year the conference will be for the AsiaPacific region instead.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Opportunities in Australia and growth of biotech industry.

Fintan Walton:

Hello and welcome to PharmaVentures business review in the special edition with Anna Lavelle, the CEO of AusBiotech here we are in Melbourne, Australia in October 2008. Welcome to the show.

Anna Lavelle:

Thanks Fintan. Pleasure to be here as always.

Fintan Walton:

Good. Anna Lavelle, this year AusBiotech is here in Melbourne and what's it like this year for AusBiotech?

Anna Lavelle:

It's fantastic you know we are really very pleased we thought with the economic environment there may be some difficulty really in getting the activity and the interest and the motivation. I was a bit interested to see what the buzz would be like, but I have to say I am pleasantly surprised. I think that it just shows how resilient the biotech industry are, the people here they've never known a free kick I suppose and they are a bit toughened to the environment and so I can see that it all goes well for the future, no one is throwing in the tale they all seem to be talking about the future, talking about partnerships. They've got about 1500 business matching - meetings already worked out as I speak. And then probably will be more before the end of the conference. So it shows to me that the activity hasn't diminished in anyway.

Fintan Walton:

Well clearly Anna, one of the things that we've noticed is that there is a even a greater presence with a pharmaceutical companies clearly coming here looking for opportunities in Australia?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Anna Lavelle

CEO

Dr Anna Lavelle was appointed inaugural Chief Executive Officer and Executive Director of AusBiotech Ltd in June 2005. AusBiotech is the peak industry body for biotechnology with over 3,000 members. AusBiotech is part of the Pharmaceutical Industry Council and Chairs the Asia/Pacific biotechnology network. Dr Lavellealso Chairs, or is a member of, various Federal and State government committees associated with biotechnology. Previously Dr Lavellewas a Senior Executive with the Australian Red Cross Blood Service (ARCBS), commencing in 1998 as Director responsible for Strategic Planning and Business Development. Prior to joining ARCBS, Dr Lavelleheld positions of Chief Executive Officer of a public health organization, Industry Lobbyist for a member organization and commenced employment as an academic at Monash University, Melbourne. Dr Lavelleholds a Doctor of Philosophy in Genetics from the University of Melbourne and is a graduate of the Australian Institute of Company Directors.

AusBiotech Ltd

AusBiotech is Australia's Biotechnology Industry Organization, which represents over 3000 members and covers the human health, agricultural, medical device, bioinformatics, environmental and industrial sectors in biotechnology. The organization is dedicated to the development, growth and prosperity of the Australian biotechnology industry by providing initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for members nationally and around the world.